EU JCA 2025 Explained: What Rare Disease Sponsors Need to Know Now
The EU Joint Clinical Assessment (JCA) is one of the most significant changes to hit market access in years.[…]
JCA is underway…what it really means for rare disease evidence
Introduction This article first appeared in the Rare Focus newsletter on LinkedIn (October 2025). The EU Joint Clinical[…]
Why Patient Voices Are Critical for EU Joint Clinical Assessment (JCA) Now
The European Union is in the midst of a transformative shift toward a harmonized Health Technology Assessment[…]
Uncovering the “Why” Behind Behaviour to Engage Rare Disease Patients and Families
Living with a rare diagnosis brings with it a unique set of challenges. Research can be sparse,[…]
Making It Easier for Patients to Find the Online Health Information They Need
Why we should be optimising content to target Google SERP features (Google Search Engine Results Page). As[…]
Exploring Lay Summaries: Collaborating with Patients for Clearer Communication
In the modern healthcare landscape, where the language of medicine can be overwhelming, the quest for clear[…]